vs
Side-by-side financial comparison of Incyte (INCY) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
Incyte is the larger business by last-quarter revenue ($1.3B vs $872.7M, roughly 1.5× Primerica, Inc.). Incyte runs the higher net margin — 23.8% vs 21.8%, a 2.1% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs 8.4%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs 4.2%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
INCY vs PRI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $872.7M |
| Net Profit | $303.3M | $190.1M |
| Gross Margin | — | — |
| Operating Margin | 23.7% | — |
| Net Margin | 23.8% | 21.8% |
| Revenue YoY | 20.9% | 8.4% |
| Net Profit YoY | 91.7% | 12.4% |
| EPS (diluted) | $1.47 | $5.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $872.7M | ||
| Q4 25 | $1.5B | $853.7M | ||
| Q3 25 | $1.4B | $839.9M | ||
| Q2 25 | $1.2B | $793.3M | ||
| Q1 25 | $1.1B | $804.8M | ||
| Q4 24 | $1.2B | $768.8M | ||
| Q3 24 | $1.1B | $774.1M | ||
| Q2 24 | $1.0B | $803.4M |
| Q1 26 | $303.3M | $190.1M | ||
| Q4 25 | $299.3M | $197.0M | ||
| Q3 25 | $424.2M | $206.8M | ||
| Q2 25 | $405.0M | $178.3M | ||
| Q1 25 | $158.2M | $169.1M | ||
| Q4 24 | $201.2M | $167.1M | ||
| Q3 24 | $106.5M | $164.4M | ||
| Q2 24 | $-444.6M | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 92.0% | — | ||
| Q3 25 | 92.8% | — | ||
| Q2 25 | 93.5% | — | ||
| Q1 25 | 93.0% | — | ||
| Q4 24 | 92.5% | — | ||
| Q3 24 | 92.4% | — | ||
| Q2 24 | 92.7% | 98.0% |
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.3% | 28.9% | ||
| Q3 25 | 32.5% | 32.3% | ||
| Q2 25 | 43.6% | 29.6% | ||
| Q1 25 | 19.5% | 27.5% | ||
| Q4 24 | 25.6% | 64.7% | ||
| Q3 24 | 12.8% | 32.9% | ||
| Q2 24 | -45.8% | 1.0% |
| Q1 26 | 23.8% | 21.8% | ||
| Q4 25 | 19.9% | 23.1% | ||
| Q3 25 | 31.1% | 24.6% | ||
| Q2 25 | 33.3% | 22.5% | ||
| Q1 25 | 15.0% | 21.0% | ||
| Q4 24 | 17.1% | 21.7% | ||
| Q3 24 | 9.4% | 21.2% | ||
| Q2 24 | -42.6% | 0.1% |
| Q1 26 | $1.47 | $5.97 | ||
| Q4 25 | $1.46 | $6.11 | ||
| Q3 25 | $2.11 | $6.35 | ||
| Q2 25 | $2.04 | $5.40 | ||
| Q1 25 | $0.80 | $5.05 | ||
| Q4 24 | $0.90 | $4.92 | ||
| Q3 24 | $0.54 | $4.83 | ||
| Q2 24 | $-2.04 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $645.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.6B | $2.5B |
| Total Assets | $7.3B | $14.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $645.8M | ||
| Q4 25 | $3.1B | $756.2M | ||
| Q3 25 | $2.5B | $644.9M | ||
| Q2 25 | $2.0B | $621.2M | ||
| Q1 25 | $1.9B | $625.1M | ||
| Q4 24 | $1.7B | $687.8M | ||
| Q3 24 | $1.3B | $550.1M | ||
| Q2 24 | $987.3M | $627.3M |
| Q1 26 | $5.6B | $2.5B | ||
| Q4 25 | $5.2B | $2.4B | ||
| Q3 25 | $4.7B | $2.3B | ||
| Q2 25 | $4.2B | $2.3B | ||
| Q1 25 | $3.7B | $2.3B | ||
| Q4 24 | $3.4B | $2.3B | ||
| Q3 24 | $3.2B | $1.9B | ||
| Q2 24 | $3.0B | $2.1B |
| Q1 26 | $7.3B | $14.7B | ||
| Q4 25 | $7.0B | $15.0B | ||
| Q3 25 | $6.3B | $14.8B | ||
| Q2 25 | $5.8B | $14.8B | ||
| Q1 25 | $5.7B | $14.6B | ||
| Q4 24 | $5.4B | $14.6B | ||
| Q3 24 | $5.0B | $14.8B | ||
| Q2 24 | $4.7B | $14.6B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
